Safety and Efficacy of Cemiplimab (PD-1 Blockade) in Selected Organ Transplant Recipients With Advanced Cutaneous Squamous Cell Carcinoma (CONTRAC)
Latest Information Update: 29 Apr 2025
At a glance
- Drugs Cemiplimab (Primary) ; Everolimus (Primary) ; Prednisone (Primary) ; Sirolimus (Primary)
- Indications Skin cancer; Squamous cell cancer
- Focus Adverse reactions
- Acronyms CONTRAC
Most Recent Events
- 23 Apr 2025 Status changed from active, no longer recruiting to completed.
- 22 Jan 2025 Planned End Date changed from 1 Jan 2025 to 1 Jan 2026.
- 01 Jan 2024 Planned End Date changed from 1 Jan 2024 to 1 Jan 2025.